WHO WE ARE
About Us
Global Regulatory Partners Japan (GRP Japan) is a pharmaceutical company dedicated to accelerating access for Japanese patients and healthcare providers to overseas medical solutions.
About the GRP Group
The Global Regulatory Partners Group (GRP Group) is the parent company of Global Regulatory Partners Japan (GRP Japan). The GRP Group is a global Marketing Authorization Holder (MAH) contract research organization (CRO) offering regulatory, clinical, safety, quality, logistics and distribution services through our Market Access Platform (MMAP).
Founded in 2011 the group has grown from a US-based consultancy into a multinational partner with offices in the USA, Japan, Brazil, China, Mexico and South Korea. Our experience supporting small and mid-sized innovators has shaped our integrated model, allowing us to help companies with limited resources achieve efficient and cost-effective access to highly regulated markets worldwide.
About GRP Japan
GRP Japan focuses on the following therapeutic areas:
- Innovative medicines
- Diabetes
- Biosimilars
- High-risk medical products
We are dedicated to improving access for patients to overseas medical therapies and technologies that often take longer to reach Japan. This is particularly true for breakthrough treatments, devices and pharmaceuticals that face complex regulatory processes.
Our expertise in Japan and overseas network makes GRP Japan a bridge between innovation abroad and patients and healthcare providers in Japan.
About the Founder
Dr. Suzan Davis
President, CEO & Founder
Dr. Davis brings over 36 years of regulatory, clinical and quality expertise from leadership roles at GSK, Pfizer, Genzyme, EMD Serono and Takeda. Her vision has always been to lower market-entry barriers for life science companies of every size, enabling them to reach patients in need more quickly across the world’s most important markets.
In Japan she has championed efforts to reduce drug lag while helping domestic innovators succeed overseas. Her leadership continues to drive GRP’s culture of innovation, collaboration and patient-first outcomes.
Message from the CEO
As the founder and CEO of GRP, my vision is to reduce barriers to market entry for life science companies of all sizes, helping them navigate strategic global markets with ease. By leveraging GRP’s infrastructure and licenses in key regions, we minimize risks and investment, facilitating a smoother market entry into some of the world’s most vital healthcare hubs.
In Japan, our mission is clear: to accelerate the introduction of innovative products and technologies, addressing the needs of Japanese patients and reducing drug lag for critical treatments. We are also dedicated to helping Japanese life science companies expand their reach globally, they have the support they need to succeed on the world stage.
At GRP, we are ensuring by a commitment to innovation, collaboration, and the advancement of global healthcare. Our passion for supporting life science companies and improving patient outcomes worldwide motivates us every day.
Together, we will continue to break down barriers, foster growth, and shape the future of healthcare by delivering impactful solutions that meet the needs of today and tomorrow.
Company Information (Japan)
- Company NameGlobal Regulatory Partners GK
- Head Office7F Toranomon 40MT Building, 5-13-1 Toranomon, Minato-ku, Tokyo 105-0001
- Capital60 million yen
- EstablishedOctober 2016
- Business DetailsManufacturing, sales and consulting of pharmaceuticals, medical devices, in vitro diagnostics, cosmetics and quasi-drugs
